The hepatitis B vaccine, often hailed as the first anti-cancer vaccine, represents a groundbreaking achievement in global public health. Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), a deadly form of liver cancer.
The hepatitis B vaccine, often hailed as the first anti-cancer vaccine, represents a groundbreaking achievement in global public health. Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), a deadly form of liver cancer. By preventing HBV infection, the vaccine directly reduces the risk of HCC, making it a powerful tool in cancer prevention.
Since its introduction, the hepatitis B vaccine has significantly reduced HBV infection rates worldwide, particularly in regions with historically high prevalence, such as Southeast Asia. This region has long borne the brunt of HBV-related diseases, with millions suffering from chronic infections and liver-related complications. Universal vaccination programs, especially those targeting newborns and infants, have been instrumental in curbing HBV transmission from mother to child, one of the primary modes of infection.
The vaccine's impact is profound—countries with high vaccination coverage have reported dramatic declines in HBV prevalence and HCC incidence among younger generations. For example, in Taiwan, a pioneer in HBV vaccination, the incidence of childhood HCC has nearly been eradicated. As global vaccination efforts expand, the hepatitis B vaccine continues to save millions of lives, offering hope for a future free from HBV and its devastating consequences, including liver cancer.
Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....
Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that...
Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...
Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...
Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...
Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.